Cytokinetics CYTK Income Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| $88.04M+377% | $18.47M+145% | $7.53M-92.0% | $94.59M+34.3% | ||
| $414.45M+22.1% | $339.41M+2.8% | $330.12M+37.1% | $240.81M+50.6% | ||
| —— | —— | —— | —— | ||
| $284.27M+32.0% | $215.31M+24.0% | $173.61M-2.5% | $177.98M+83.9% | ||
| $700.3M+26.2% | $554.72M+10.1% | $503.74M+20.3% | $418.79M+63.1% | ||
| -$612.26M-14.2% | -$536.25M-8.1% | -$496.21M-53.1% | -$324.2M-74.0% | ||
| -695.4%+2,207pp | -2,902.7%+3,687pp | -6,589.7%-6,247pp | -342.8%-78.2pp | ||
| $45.58M+20.9% | $37.7M+33.2% | $28.31M+45.8% | $19.41M+18.1% | ||
| $48.42M-6.0% | $51.53M+86.5% | $27.63M+144% | $11.34M— | ||
| -$784.96M-33.2% | -$589.53M-12.0% | -$526.24M-35.3% | -$388.96M-80.6% | ||
| -891.6%+2,300pp | -3,191.1%+3,798pp | -6,988.6%-6,577pp | -411.2%-105pp | ||
| -$6.53-24.1% | -$5.26+3.5% | -$5.45-27.3% | -$4.28-53.4% | ||
| -$602.13M-14.3% | -$526.72M-8.8% | -$484.31M-52.1% | -$318.39M-73.0% | ||
| -683.9%+2,167pp | -2,851.1%+3,581pp | -6,431.8%-6,095pp | -336.6%-75.3pp | ||
| -$612.26M-14.2% | -$536.25M-8.1% | -$496.21M-53.1% | -$324.2M-74.0% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Cytokinetics's revenue?
- Cytokinetics (CYTK) generated $105.8M in revenue over the trailing twelve months, up 450.6% year over year.
- Is Cytokinetics profitable?
- Cytokinetics is not currently profitable: it reported a net loss of $829.6M over the trailing twelve months, a -784.0% net margin.
- What is Cytokinetics's earnings per share?
- Cytokinetics's diluted EPS over the trailing twelve months is $-6.84.
- Where does Cytokinetics's income statement data come from?
- Every line is extracted from Cytokinetics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
